chronic heart failure
Conditions
Interventions
automated physiological monitoring including daily body weight, blood pressure, and pulse rate by web linked home telemonitoring system, and patient education by nurse with the use of the home telemon
Sponsors
Department of Cardiovascular Medicine, Saga university
Hokkaido university Hyogo college of medicine National Cerebral and Cardiovascular Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients currently scheduled for discharge or discharged within 30 days from heart failure hospitalization; New York Heart Association functional class II or III; age 20 or older
Exclusion criteria
Exclusion criteria: currently implanted or scheduled for pacemaker, implantable cardioverter defibrillator, or bi-ventricular pacemaker (with defibrillator), because the scale for present study emits a faint alternating current to measure body impedance; advanced renal insufficiency (i.e. serum creatinine 3.0 mg/ld or more); severe liver dysfunction; planned percutaneous coronary intervention or coronary artery bypass grafting; limited life expectancy because of malignant disease; severe cognitive impairment or mental illness; pregnancy; deemed unable to stand on a scale safely; no access to a telephone line
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to all-cause death or readmission for heart failure decompensation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. time to all-cause death 2. time to cardiovascular death 3. time to all-cause readmissions 4. time to cardiovascular readmissions 5. time to readmissions for heart failure decompensation 6. changes in New York Heart Association functional class (NYHA) 7. cost effectiveness 8. changes in left ventricular ejection fraction (EF) 9. changes in N-terminal pro-BNP (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), pentraxin3 (PTX3), adipose triglyceride lipase (ATGL), high-sensitivity troponin T (hsTnT), receptor for advanced glycation end products (RAGE), and high-molecular weight adiponectin 10. cognitive function (Mini Mental State Examination; MMSE) 11. patient's self efficacy (General Self Efficacy Scale; GSES) 12. heart failure related quality of life (QOL) as measured by the Minnesota Living with Heart Failure (MLWHF) 13. adherance for medication 14. anxiety and deession as measured by Patient Health Questionnaire 9 (PHQ-9) | — |
Countries
Japan
Contacts
Public ContactNorihiko Kotooka
Saga university cardiovascular medicine
Outcome results
None listed